Literature DB >> 18789973

Immunization with plasmid DNA encoding influenza A virus nucleoprotein fused to a tissue plasminogen activator signal sequence elicits strong immune responses and protection against H5N1 challenge in mice.

Mengcheng Luo1, Pan Tao, Junwei Li, Siyu Zhou, Deyin Guo, Zishu Pan.   

Abstract

DNA vaccination is an effective means of eliciting both humoral and cellular immunity. Most of influenza vaccines targeted at hemagglutinin (HA) show efficient immunogenicity for protecting subjects against influenza virus infection. However, major antigenic variations of HA may facilitate the virus in developing resistance against such vaccines. DNA vaccines encoding conserved antigens protect animals against diverse viral subtypes, but their potency requires further improvement. In the present study, a DNA vaccine encoding the conserved nucleoprotein (NP) with a tissue plasminogen activator (tPA) signal sequence (ptPAs/NP) was generated, and immune responses were examined in vaccinated mice. A higher level of NP expression and secretion was observed in lysates and supernatants of the cells transfected with ptPAs/NP when compared to a plasmid encoding the wild-type full-length NP (pflNP). Immunofluorescence studies showed the cytoplasmic localization of the NP protein expressed from ptPAs/NP, but not from pflNP. In mice, the ptPAs/NP vaccine elicited higher levels of the NP-specific IgG and CD8(+) T cell-stimulating responses than that of pflNP. Vaccination with ptPAs/NP efficiently cleared the homologous H5N1 influenza virus in the infected lungs and induced partial cross-protection against heterologous, highly pathogenic H5N1 strains in mice. Our results may contribute to the development of protective immunity against diverse, highly pathogenic H5N1 virus subtypes.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18789973     DOI: 10.1016/j.jviromet.2008.08.011

Source DB:  PubMed          Journal:  J Virol Methods        ISSN: 0166-0934            Impact factor:   2.014


  16 in total

Review 1.  Protein engineering strategies for the development of viral vaccines and immunotherapeutics.

Authors:  Jayne F Koellhoffer; Chelsea D Higgins; Jonathan R Lai
Journal:  FEBS Lett       Date:  2013-10-21       Impact factor: 4.124

2.  Bioinformatics in new generation flavivirus vaccines.

Authors:  Penelope Koraka; Byron E E Martina; Albert D M E Osterhaus
Journal:  J Biomed Biotechnol       Date:  2010-05-10

3.  Transgene optimization, immunogenicity and in vitro efficacy of viral vectored vaccines expressing two alleles of Plasmodium falciparum AMA1.

Authors:  Sumi Biswas; Matthew D J Dicks; Carole A Long; Edmond J Remarque; Loredana Siani; Stefano Colloca; Matthew G Cottingham; Anthony A Holder; Sarah C Gilbert; Adrian V S Hill; Simon J Draper
Journal:  PLoS One       Date:  2011-06-16       Impact factor: 3.240

4.  Induction of a protective response in mice by the dengue virus NS3 protein using DNA vaccines.

Authors:  Simone M Costa; Anna Paula Yorio; Antônio J S Gonçalves; Mariana M Vidale; Emmerson C B Costa; Ronaldo Mohana-Borges; Marcia A Motta; Marcos S Freire; Ada M B Alves
Journal:  PLoS One       Date:  2011-10-21       Impact factor: 3.240

5.  Comparative assessment of vaccine vectors encoding ten malaria antigens identifies two protective liver-stage candidates.

Authors:  Rhea J Longley; Ahmed M Salman; Matthew G Cottingham; Katie Ewer; Chris J Janse; Shahid M Khan; Alexandra J Spencer; Adrian V S Hill
Journal:  Sci Rep       Date:  2015-07-03       Impact factor: 4.379

6.  Design, Construction and Cloning of Truncated ORF2 and tPAsp-PADRE-Truncated ORF2 Gene Cassette From Hepatitis E Virus in the pVAX1 Expression Vector.

Authors:  Fatemeh Farshadpour; Manoochehr Makvandi; Reza Taherkhani
Journal:  Jundishapur J Microbiol       Date:  2015-12-13       Impact factor: 0.747

7.  Construction and evaluation of the novel DNA vaccine harboring the inhibin α (1-32) and the RF-amide related peptide-3 genes for improving fertility in mice.

Authors:  Xingang Dan; Li Han; Hasan Riaz; Xuan Luo; Xiaoran Liu; Zhenglu Chong; Liguo Yang
Journal:  Exp Anim       Date:  2015-10-02

8.  ChAdOx1 and MVA based vaccine candidates against MERS-CoV elicit neutralising antibodies and cellular immune responses in mice.

Authors:  Naif Khalaf Alharbi; Eriko Padron-Regalado; Craig P Thompson; Alexandra Kupke; Daniel Wells; Megan A Sloan; Keith Grehan; Nigel Temperton; Teresa Lambe; George Warimwe; Stephan Becker; Adrian V S Hill; Sarah C Gilbert
Journal:  Vaccine       Date:  2017-06-01       Impact factor: 3.641

9.  A novel vaccine against Crimean-Congo Haemorrhagic Fever protects 100% of animals against lethal challenge in a mouse model.

Authors:  Karen R Buttigieg; Stuart D Dowall; Stephen Findlay-Wilson; Aleksandra Miloszewska; Emma Rayner; Roger Hewson; Miles W Carroll
Journal:  PLoS One       Date:  2014-03-12       Impact factor: 3.240

10.  A Crimean-Congo hemorrhagic fever (CCHF) viral vaccine expressing nucleoprotein is immunogenic but fails to confer protection against lethal disease.

Authors:  S D Dowall; K R Buttigieg; S J D Findlay-Wilson; E Rayner; G Pearson; A Miloszewska; V A Graham; M W Carroll; R Hewson
Journal:  Hum Vaccin Immunother       Date:  2016       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.